US FDA approves Revolution Medicines' pancreatic cancer drug
In a 500-patient trial, the pill nearly doubled median survival to 13.2 months and reduced death risk by 60%, researchers said.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
194 Articles
194 Articles
The Food and Drug Administration (FDA) approved on Wednesday a new drug for advanced pancreatic cancer, inaugurating a new era of treatment for a disease that has long been considered one of the most difficult to treat in medicine. This drug, which is taken in two pills a day, is the first of its kind and has excited both cancer specialists and patients. It is not a cure, but it is the first treatment that substantially prolongs the life of pati…
The United States on Wednesday approved a drug, Rasonque, considered by experts to be the most significant advance ever in the fight against pancreatic cancer. This tablet treatment will extend the lives of patients.
FDA approves breakthrough drug for pancreatic cancer treatment
US regulators on Wednesday approved a drug that slows pancreatic cancer, a breakthrough treatment for a disease that kills seven out of eight patients within five years. In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy. “This is life-altering,” an oncologist told The Wall Street Journal. Researchers spent decades trying to target a group of mutations called R…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
